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Abstract
The objective of this study is to investigate cognitive performance in a first-episode psycho-
sis sample, when stratifying the interaction by cannabis use and familial or non-familial psy-
chosis. Hierarchical-regression models were used to analyse this association in a sample of
268 first-episode psychosis patients and 237 controls. We found that cannabis use was
associated with worse working memory, regardless of family history. However, cannabis
use was clearly associated with worse cognitive performance in patients with no family his-
tory of psychosis, in cognitive domains including verbal memory, executive function and
global cognitive index, whereas cannabis users with a family history of psychosis performed
better in these domains. The main finding of the study is that there is an interaction between
cannabis use and a family history of psychosis in the areas of verbal memory, executive
function and global cognition: that is, cannabis use is associated with a better performance
in patients with a family history of psychosis and a worse performance in those with no fam-
ily history of psychosis. In order to confirm this hypothesis, future research should explore
the actual expression of the endocannabinoid system in patients with and without a family
history of psychosis.
PLOS ONE | DOI:10.1371/journal.pone.0160949 August 11, 2016 1 / 16
a11111
OPEN ACCESS
Citation: González-Pinto A, González-Ortega I,
Alberich S, Ruiz de Azúa S, Bernardo M, Bioque M,
et al. (2016) Opposite Cannabis-Cognition
Associations in Psychotic Patients Depending on
Family History. PLoS ONE 11(8): e0160949.
doi:10.1371/journal.pone.0160949
Editor: Therese van Amelsvoort, Maastricht
University, NETHERLANDS
Received: February 5, 2016
Accepted: July 27, 2016
Published: August 11, 2016
Copyright: © 2016 González-Pinto et al. This is an
open access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: The authors would like to thank the
following institutions for their funding contributions:
the Spanish Ministry of Economy and
Competitiveness (Ref. ISCIII 2009-2011:PI 080208),
the Instituto de Salud Carlos III-European Fund for
Regional Development (PI10/01430, PI10/01746,
PI11/01977, PI11/02708, 2011/1064, PI12/02077,
PI13/02252, PI13/00451 and PI14/01900, PI11/
02831), the Centre for Biomedical Research in the
Mental Health Network (CIBERSAM), the Health
Introduction
Cannabis is the most commonly used illicit drug in psychosis [1]. Moreover, it is a controver-
sial drug, with detractors and supporters, which has a high social impact. There is strong evi-
dence that long-term cannabis use is associated with decreased functionality in psychosis [2].
However, recent meta-analyses have also found associations between a history of cannabis use
and improved cognition in psychosis [3,4]. Furthermore, the study by Yücel et al. [4] found
that patients with first-episode psychosis (FEP) and earlier cannabis use had better cognitive
performance than patients with later onset of use. There are also numerous contrasting find-
ings in relation to neurobiological research on cannabis and cognition in psychosis. Whereas
some studies have revealed cognitive impairment [5–10] and deficits in grey matter, lateral
ventricle enlargement, and brain abnormalities [11–13] in FEP cannabis users, other authors
have suggested that FEP related to cannabis use is associated with better cognitive functioning
and fewer brain abnormalities [4,14–16]. In addition to these controversial results, a deleteri-
ous effect of cannabis on cognition has been demonstrated in both animal models [17] and
healthy subjects [18]. However, an increased vulnerability to the deleterious effect of cannabis
on cognition has been found in patients with schizophrenia as compared to healthy controls,
specifically in the memory and learning domains [9]. In contrast, other authors have reported
that FEP patients who used cannabis have lower cognitive impairment relative to healthy con-
trols in relation to visual memory, working memory, planning and reasoning domains [6].
Moreover, shared effects of genetics and family environment have been suggested as influential
in the development of brain structure and cannabis use. Pagliaccio et al. [6] have reported that
cannabis exposure is associated with small subcortical structures in a large sample of normal
twins/siblings discordant for cannabis abuse. However, not only were these variations within
the normal range, they were also primarily attributed to familial factors, rather than to a direct
neurotoxic effect [6]. In respect of cognitive impairment, psychotic patients with a family his-
tory (FH) of psychosis had previously shown worse cognition than patients with no FH of psy-
chosis [19–24].
As the data regarding the relation between cannabis use and cognition are highly controver-
sial, and cognitive deficits are core symptoms of schizophrenia, it was considered possible that
not all cases of psychosis had the same cognitive associations with cannabis use. Therefore, we
focused on FH of psychosis, and split the sample into two different groups according to this
variable: people with FEP and with or without FH of psychosis.
We conducted a study to investigate the associations between cannabis use and cognition in
patients with psychosis, distinguishing the interactions by having a familial vs. no familial his-
tory of psychosis. The specific aims of the study were: 1) to compare cognition between patients
with a family history of psychosis (FH+) and patients with no family history of psychosis (FH-)
as regards cannabis use; 2) to determine the independent effect of cannabis use and the FH of
psychosis on cognition and the interaction between these two factors; and 3) to analyse the
associations between cannabis use and cognition in healthy controls and to compare them with
those in FEP patients.
Materials and Methods
Subjects
This work was part of the “Phenotype-genotype and environmental interaction: application of a
predictive model in first psychotic episodes” study (PEPs study, from its acronym in Spanish)
[25]. Patients were matched with healthy controls by age (±10%), sex and parental socio-eco-
nomic level, and assessed using the Hollingshead-Redlich index of social position [26] (±1 level).
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Patients and controls were required to be fluent in Spanish and to provide informed con-
sent. The clinicians who contributed to recruitment of the sample assessed the capacity of
patients to provide informed consent via a clinical interview. In the cases of patients not able to
provide consent, or of patients who were minors, a legally authorized representative gave con-
sent on behalf of the participants. Moreover, patients were required to have had psychotic
symptoms of less than 12 months’ duration.
Exclusion criteria for patients and controls were: mental retardation according to the
DSM-IV [27] (including both an IQ below 70, as determined using the test described in
Table 1, and poor functionality), a history of head trauma with loss of consciousness, and
organic illness with mental repercussions. Controls were also excluded if they had suffered, or
were suffering, from psychotic disease, were experiencing major depression according to the
DSM-IV [28,29], or had a first-degree family member with a history of psychotic disease.
The study was approved by the following clinical research ethics committees: Araba Univer-
sity Hospital, Hospital Clinic of Barcelona, Gregorio Marañon General University Hospital,
Navarre Hospital Complex, and the centres included in the PEPs Group.
Initially, 335 FEP patients and 253 healthy controls were included in the study. Of these sub-
jects, 69 (53 patients and 16 controls) were excluded for not having completed seven or more
neuropsychological tests. Moreover, 14 patients were excluded because of a lack of data on FH
of psychosis (first- or second-degree). As a result, the final study sample consisted of 268
patients and 237 controls. Patients were distributed into two groups, depending on whether or
not they had an FH of psychosis. A total of 88 patients were FH+, whereas 180 were FH-. For
cognitive comparison, each group was split into two subgroups: one group of cannabis users
(FH- = 73; FH+ = 34; controls = 37) and one group of non-users (FH- = 107; FH+ = 54;
controls = 200).
Data collection
Socio-demographic and clinical data were collected at baseline and cognitive assessment was
performed at two months follow-up, in order to ensure the psychopathologic stability of
patients. The assessment protocol is fully discussed in the paper by Bernardo et al. [25].
The socio-demographic variables included were sex, age, civil (marital) status, educational
background, parental socio-economic status, and occupation.
Adult patients were diagnosed using the SCID-I and II [28], whereas the K-SADS-PL [29]
was used for patients aged below 18 years, in accordance with the DSM-IV criteria. Patients
were classified into three groups according to diagnosis: 1) those with schizophrenia-spectrum
disorders, including schizophrenia, schizoaffective disorders and schizophreniform disorders;
2) those with affective-spectrum disorders, such as bipolar disorder, manic and depressive epi-
sodes; and 3) those with other psychoses, such as substance-induced psychosis, brief psychotic
disorders, and psychoses not otherwise specified.
Pharmacological treatment was also recollected at baseline. Antipsychotic daily doses were
converted to chlorpromazine equivalents [30].
Use of cannabis and other substances (including alcohol and tobacco) was assessed in
patients and healthy controls using the European Adaptation of a Multidimensional Assess-
ment Instrument for Drug and Alcohol Dependence (EuropASI), and was categorized into
four groups (no use, use, abuse and dependence) according to EuropASI scores [31]. Age of first
use was also recorded.
The Family History of Psychosis-Related Disorder (FHPRD) was assessed using a protocol
that evaluated first- and second-degree family history of mental illnesses, according to
DSM-IV criteria. In the case of patients under 18 years of age, at least one adult relative was
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interviewed for each participant. The FHPRD was positive when one or several members of the
family (first- or second-degree) presented a diagnosis of psychotic disorder with delusions or
hallucinations requiring psychiatric treatment.
Cognitive performance was evaluated using the following cognitive domains: processing
speed, attention, verbal memory, working memory, executive function and estimated premor-
bid IQ. A Cognitive Global Index (CGI) was calculated by averaging the scores of the cognitive
Table 1. Development of the cognitive domains.
Cognitive
domain
Neuropsychological subtests Description of test used for cognitive domain scores
Estimated
premorbid IQ
Vocabulary subtest of WAIS-IIIa/
WISC-IVb
Give oral deﬁnitions for words. Measure: direct score and standardized score.Estimated
premorbid IQ is calculated from the standardized score: (SS × 5) + 50.
Processing speed Trail Making Testc-form A Connect in proper order, by making pencil lines, 25 encircled numbers randomly arranged
on a page.Measure: time to complete this (form A)
Stroop Test word and colour conditiond Read the words and the colours of a series of XXXX as quickly as possible in 45 s.
Measure: number of items completed.
Attention CPT-IIe Respond to a series of letters on a computer screen by pressing a key when you detect
letters other than the letter “X”. The assessment contains six blocks that vary in the rate of
submission of the letters. Measure: mean response sensitivity (D-prime).
Verbal memory TAVECf Recall as many words as possible from a list of 16 words read aloud by the tester. The
procedure is repeated ﬁve times, and recall is tested immediately and after a delay.
Measure: total number of words recalled after the ﬁve trials, immediately and delayed.
Working memory Digit Span subtest of the WAIS-IIIa/
WISC-IVb
Repeat a number sequence in the same and order as presented and in reverse. Measure:
total number of series correctly repeated forwards, backwards, and the sum of both.
Letter and number sequencing of the
WAIS-IIIa/ WISC-IVb
Listen to a combination of numbers and letters read aloud by the tester and reorganize the
sequence, listing ﬁrst the numbers in ascending order and then the letters in alphabetical
order. Measure: number of correct sequences.
Executive
function
FAS testg Generate as many words as possible beginning with F, A and S, in three separate trials of
60 s. Measure: the sum of all correct responses
Animal wordsh Produce as many animal names as possible in a 1-min period. Measure: number of correct
responses.
Trail Making Testc-form B Draw lines connecting characters, alternating sequentially between numbers and letters.
Measure: time to complete this (form B), B/A ratio (time to complete form B divided by time
to complete form A).
WCSTi Complete a complex task of categorization set shifting, and respond to feedback from the
computer.Measure: number of completed categories and percentage of conceptual
responses, total errors and perseverative errors.
Stroop Testd- interference condition Name the colour in which the colour names are printed, disregarding their verbal content.
Measure: Interference Index (WC −WxC /W+ C).
Cognitive Global
Index
Processing speed A Global Cognitive Index score was calculated by averaging scores for all cognitive
domains, except the estimated premorbid IQ.Attention
Verbal memory
Working memory
Executive function
aWechsler Adult Intelligence Scale III (WAIS-III) [33].
bWechsler intelligence Scale for children-IV (WISC-IV) [34].
cTrail Making Test [35].
dStroop Test [36].
eConners’ Continuous Performance Test (CPT-II) [37].
fTest de Aprendizaje Verbal España-Complutense (TAVEC) [38].
gControlled Oral Word Association Test (FAS test) [39].
hAnimal words [40].
iWisconsin Card Sorting Test (WCST) [41].
doi:10.1371/journal.pone.0160949.t001
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domains, except the estimated premorbid IQ, which was used as an adjustment variable in the
statistical analyses. Development of these domains is reported in the papers by Bernardo et al.
[25] and Cuesta et al. [32] (Table 1).
Statistical Analyses
Differences in socio-demographic variables between FH+ and FH- patients and healthy con-
trols were analysed using one-way ANOVA tests for continuous variables and the Chi-Squared
test for categorical variables. For those significant differences between groups, a post-hoc anal-
ysis was performed.
With regard to cognitive measures, Z-scores were derived, based on the means and standard
deviations of the control group to standardize the different measurement scales used in the neuro-
psychological tests. Composite scores for cognitive domains represented by more than one mea-
sure were calculated by taking the mean of all the Z-scores included in each cognitive domain.
Cronbach’s alpha was calculated to assess the internal consistency of the composite scores, and
gave a value of 0.84 for the processing speed domain, 0.82 for verbal memory, 0.73 for working
memory and 0.76 for executive function. Since all coefficients indicate moderate reliability, we
decided to use these domains to analyse the relationship between cannabis use and cognition.
One-way ANOVA tests were performed to assess differences in patient cognition between
groups of cannabis users (no use, use, abuse and dependence) with/without FH of psychosis.
Subsequently, Bonferroni post-hoc tests were used to determine the groups for which differ-
ences in ANOVA tests were found. Differences between controls with/without cannabis use at
baseline were compared using Student’s t-test for independent samples.
Hierarchical-regression models were developed to assess the association between FH of psy-
chosis, cannabis use and cognition. Cognitive domains were taken as dependent variables in
these models. Cannabis use at baseline (presence/absence) and the subject variable (FH+
patient, FH- patient, controls) were introduced as independent variables. In addition, the inter-
action between cannabis use and subject variable was also considered in order to assess the
combined effect of these variables on cognition. We identified the following variables as poten-
tial confounders: sex, age, occupation, educational level, civil status, alcohol and tobacco con-
sumption, and IQ, and, after verifying the independence of significant potential confounders
(occupation, educational level, alcohol, tobacco consumption and estimated premorbid IQ),
the models were finally adjusted for estimated premorbid IQ and alcohol consumption.
To facilitate interpretation and comparison of groups in the hierarchical-regression models
developed to analyse the cognitive domains, FH- patients were used as the reference group,
while, for cannabis use at baseline, non-user patients was the reference category.
All statistical analyses were performed using the R statistical package, version 3.1.2 [42].
Results
Baseline characteristics
The baseline characteristics for controls and FH+ and FH- patients are summarized in Table 2.
Patients (FH+ and FH-) were less likely to have a university education (P<0.001) and were more
likely to be tobacco (P<0.001) and cannabis users than were controls (P<0.001). In contrast, con-
trols were more commonly active workers (46% vs. 19.5% and 12.8%, respectively, P<0.001) and
alcohol users (65% vs. 48.2% and 47.9%, respectively, P<0.001). Statistically significant differences
were also found between controls and patients in respect of estimated premorbid IQ (P<0.001),
with FH+ patients having the lowest scores and close to 16 points below that for controls. In the
post-hoc analysis, all the significant differences were between patients (FH+ and FH-) and con-
trols. Moreover, a comparison of estimated premorbid IQ between cannabis users and non-users
Cannabis, Family and Psychosis
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showed that the latter group had a significantly higher IQ than patients who were cannabis users.
On analysis, this relationship was only found to be significant in the FH- group. Finally, antipsy-
chotic doses for both groups were compared, and there were no significant differences.
Neuropsychological results
S1 Table shows the Z-scores for the cognitive domains for each group, depending on cannabis
use and FH of psychosis.
Statistically significant associations were found in all cognitive domains, except for Atten-
tion in regression models. The results are summarized in Table 3 and Fig 1. Fig 2 shows the
interactions between subjects and cannabis use in the domains in which a statistically signifi-
cant interaction was found.
Controls had better scores than FH- patients for the processing-speed domain, while FH+
patients were the worst group, with the lowest scores. Cannabis use had no impact on any group.
A significant interaction between cannabis use and the subject-type variable was obtained
for the verbal memory domain. As a consequence, whereas controls attained the best values in
this domain, the group of FH+ cannabis users had the best estimated score amongst patients,
while FH+ non cannabis users had the worst score (Fig 2).
Both cannabis use and FH were significantly related to inferior working memory, although
their interaction was not significantly associated with this domain. As a consequence, cannabis
users (regardless of whether they were patients or controls) had lower scores in this domain
than did non-users. The same occurred with FH+ patients, who had worse scores than FH-
ones (regardless of whether or not cannabis was used) (Fig 3).
With regard to executive function, a statistically significant interaction with cannabis use
was obtained in FH+/FH- patients (Table 3). The group with the best estimated scores in this
domain was that of FH- non-cannabis users, whereas FH+ non-user patients had the worst esti-
mated executive function. The control group had the highest scores, irrespective of cannabis
consumption (Fig 2).
Finally, both cannabis use and the subject-type variable interacted significantly in the Global
Cognitive Index (GCI) domain (Table 3). Indeed, as was the case with the executive-function
Table 2. Baseline characteristics of controls and FH+ and FH- patients.
FH+ patients (n = 88) FH- patients (n = 180) Controls (n = 237) Statistic
Sex Female 30 (34.1%) 54 (30%) 84 (35.4%) X2 = 1.75, P = 0.417
Age 24.17 (5.75) 23.47 (5.80) 24.33 (6.43) F = 1.83, P = 0.161
Educational level Primary education 19 (21.6%) 41 (22.8%) 17 (7.2%) X2 = 60.74, P<0.001
Secondary education 57 (64.8%) 112 (62.2%) 119 (50.2%)
University 12 (13.6%) 27 (15%) 101 (42.6%)
Civil status Single 73 (83%) 162 (90%) 200 (84.4%) X2 = 2.48, P = 0.242
Married 6 (6.9%) 11 (6.1%) 19 (8.2%)
Other 9 (10.2%) 7 (3.9%) 18 (7.6%)
Occupation Working 17 (19.5%) 23 (12.8%) 109 (46%) X2 = 94.85, P<0.001
Student 39 (44.8%) 80 (44.4%) 109 (46%)
Other 31 (35.6%) 77 (42.8%) 19 (8%)
Current alcohol use Yes 39 (48.2%) 81 (47.9%) 145 (65%) X2 = 13.91, P = 0.001
Current tobacco use Yes 58 (68.2%) 108 (63.5%) 77 (34.8%) X2 = 43.64, P<0.001
Current cannabis use Yes 34 (38.6%) 73 (43.2%) 37 (16.6%) X2 = 37.25, P<0.001
Estimated premorbid IQ 91.53 (16.56) 92.86 (14.64) 107.48 (14.18) F = 66.37, P<0.001
Antipsychotic dose (mg/day) 592.84 (476.27) 550.26 (431.72) NA t = -0.73, p = 0.467
doi:10.1371/journal.pone.0160949.t002
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domain, FH- patients who did not use cannabis were the patient group with the best estimated
score in the GCI, while FH+ non-cannabis users had the worst estimated score in this domain.
Controls (using cannabis or not) gave the highest scores in the GCI (Fig 2).
Discussion
The two main findings of this study are that cannabis use is associated with inferior working
memory in FEP patients, regardless of having a positive FH for a psychosis-related disorder,
and that cannabis is clearly associated with inferior cognitive performance in FH- patients in
relation to the verbal-memory, executive-function, and GCI domains, while FH+ cannabis
users showed better cognition in these domains. These findings are relevant and have transla-
tional value, because treatment of cannabis use requires different approaches, depending on
FH of psychosis. The association found between cannabis use and cognitive deficits in these
patients varied depending on FH. These results clarify some of the controversies concerning
Table 3. Hierarchical-regressionmodels between subject type, cannabis use and cognition.
Variables in the modela β P-value 95% CI R2
Processing speed Cannabis: users (vs. ref) 0.002 0.990 -0.297, 0.280 0.315
Subject type: FH+ (vs. ref) -0.392 0.012 -0.680, -0.071
Subject type: Controls (vs. ref) 0.626 0.003 0.410, 0.885
Cannabis*Subject type: users*FH+ patients (vs. ref) 0.344 0.170 -0.139, 0.844
Cannabis*Subject type: users*controls (vs. ref) -0.174 0.417 -0.590, 0.248
Attention Cannabis: users (vs. ref) 0.113 0.253 -0.073, 0.308 0.055
Subject type: FH+ (vs. ref) 0.053 0.604 -0.152, 0.247
Subject type: Controls (vs. ref) -0.113 0.160 -0.280, 0.033
Cannabis*Subject type: users*FH+ patients (vs. ref) -0.224 0.187 -0.556, 0.103
Cannabis*Subject type: users*controls (vs. ref) -0.199 0.166 -0.476, 0.082
Verbal memory Cannabis: users (vs. ref) -0.262 0.079 -0.550, 0.036 0.378
Subject type: FH+ (vs. ref) -0.324 0.046 -0.603, 0.004
Subject type: Controls (vs. ref) 0.748 <0.001 0.530, 1.007
Cannabis*Subject type: users*FH+ patients (vs. ref) 0.720 0.004 0.219, 1.211
Cannabis*Subject type: users*controls (vs. ref) -0.096 0.659 -0.528, 0.333
Working memory Cannabis: users (vs. ref) -0.479 0.043 -0.936, -0.019 0.116
Subject type: FH+ (vs. ref) -0.571 0.020 -1.021, -0.066
Subject type: Controls (vs. ref) 0.018 0.927 -0.325, 0.423
Cannabis*subject type: users*FH+ patients (vs. ref) 0.654 0.101 -0.129, 1.427
Cannabis*subject type: users*controls (vs. ref) 0.260 0.447 -0.417, 0.916
Executive Function Cannabis: users (vs. ref) -0.171 0.019 -0.305, -0.018 0.266
Subject type: FH+ (vs. ref) -0.208 0.005 -0.342, -0.051
Subject type: controls (vs. ref) 0.159 0.007 0.062, 0.294
Cannabis*subject type: users*FH+ patients (vs. ref) 0.224 0.047 0.007, 0.476
Cannabis*subject type: users*controls (vs. ref) 0.175 0.091 -0.045, 0.363
Cognitive global Index Cannabis: users (vs. ref) -0.134 0.118 -0.303, 0.034 0.407
Subject type: FH+ (vs. ref) -0.305 <0.001 -0.475, -0.134
Subject type: controls (vs. ref) 0.287 <0.001 0.154, 0.420
Cannabis*subject type: users*FH+ patients (vs. ref) 0.314 0.031 0.029, 0.598
Cannabis*subject type: users*controls (vs. ref) -0.014 0.910 -0.252, 0.225
a Variables in the model: IQ, alcohol at baseline, cannabis use at baseline (yes/no), subject type (FH- patients/ FH+ patients/controls).
References groups: for the use of cannabis at baseline: no use; for the subject type variable: FH- patients.
doi:10.1371/journal.pone.0160949.t003
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the association between cannabis use and cognitive deficits, and should be taken into consider-
ation for the prevention and treatment of these patients.
As shown in Table 3, cannabis users (patients and controls) had worse working memory
and executive function to non-users, when FH was not considered. Acute administration of
THC causes more deleterious cognitive effects in patients with psychosis than in healthy con-
trol subjects [9]. Some studies have found cognitive impairment in FEP cannabis-user patients
compared with control subjects [9] and cognitive deficits in processing speed and verbal mem-
ory [43], along with brain abnormalities [11–13]. In contrast, other authors have reported that
psychosis patients who use cannabis have better cognitive functioning in some domains than
do non-cannabis users [4,14–16], with fewer brain abnormalities and less attention and execu-
tive impairment than patients who have never used cannabis [44].
These conflicting findings are probably mediated by different moderators. Yücel et al. [4]
considered that there is probably a subgroup of cannabis users with psychosis who have better
premorbid adjustment and cognitive performance. Meijer et al. [43] also found that current
cannabis use is associated with poorer cognitive performance, but that lifetime cannabis users
may have a higher cognitive potential. This does not mean that cannabis has a beneficial effect
on cognition; on the contrary, it worsens cognitive performance, although some of these indi-
viduals had better premorbid capacities. Our study was performed on FEP, and all patients
were included at the same time, consequently limiting the possible moderating effect of time.
According to Van Winkel et al. [10], the deleterious effect of cannabis use on cognition in
patients with psychosis may be moderated by the AKT1 gene. These authors showed that can-
nabis-user patients who carried the CC variant in the AKT1 gene performed worse in attention
Fig 1. Graphical representation of the regression models.
doi:10.1371/journal.pone.0160949.g001
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tests than patients with this genotype who did not use cannabis, whereas cannabis users with
the TT variant in AKT1 performed as well as, or better than, cannabis non-users [45]. We have
not attempted to identify genetic differences amongst our patients in this study.
The different interaction of cannabis use depending on the FH of psychosis has not been
demonstrated previously. Although we cannot state causal relationships, this interaction is suf-
ficiently large as to be unlikely to be due to chance. This suggests that the FH-cannabis interac-
tion affects more complex cognitive functions (for example, executive function), which depend
on multiple cognitive processes, more than it does basic functions (for example, attention).
These data support previous studies on cognition and cannabis use in patients with schizophre-
nia [7,8]. However, FH+ cannabis users show better functioning in complex cognitive domains,
as reported in recent meta-analyses [4]. This finding must be interpreted with caution because,
considering the data as a whole, cannabis use is associated with worse working memory regard-
less of having FH of psychosis or not. Our findings do not support the idea of better cognitive
performance in patients with cannabis use; rather, they suggest an FH of psychosis as a possible
factor contributing to the controversial results found in the literature.
A possible explanation for the differential effects of cannabis depending on FH in patients
could be a distinct effect of cannabis compounds on the central nervous system of FH+
patients. Although the endocannabinoid system is involved in the development of cognitive
deficits associated with cannabis use and schizophrenia [46], it is well known that cannabidiol
Fig 2. Statistically significant interactions between cannabis use and subject type.
doi:10.1371/journal.pone.0160949.g002
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(CBD) and tetrahydrocannabinol (THC) have opposing effects in various brain structures
involved in psychiatric disorders, notably the striatum, cingulate, prefrontal cortex, hippocam-
pus and amygdala. CBD might protect neurons against the possible neurotoxic effects of THC,
meaning that it could inhibit the cognitive and psychotomimetic effects of THC. Moreover,
CBD has been found to protect users against both psychotic symptoms and memory
impairment [47]. One possible explanation for our findings is that the protective role of CBD is
expressed better in FH+ patients than in FH- ones. Future research could explore the real
expression of the endocannabinoid system in FH+ and FH- patients to confirm this hypothesis.
Our findings suggest that FH is an important factor to consider when studying the effects of
cannabis on cognition. Our results support some differences in cognitive deficits when taking
into account cannabis use and FH. Cannabis and FH are separately associated with poorer cog-
nitive functioning, while their interaction has no significant effects on cognition and impacts
differently depending on whether FH is present or not.
When comparing cognition without considering cannabis use, FH+ patients had worse CGI,
processing speed, verbal and working memory, and executive function than FH- patients. Pre-
vious studies have shown that FH+ patients have greater cognitive deficits [19–24]. Moreover,
some research has shown that FH+ patients and patients with a high clinical risk of psychosis
have cognitive deficits, and that co-occurring attenuated symptoms and genetic risk are related
to more severe cognitive deficits [20,48]. Bora et al. [20] suggested that cognitive impairment
Fig 3. Association between cannabis use and workingmemory.
doi:10.1371/journal.pone.0160949.g003
Cannabis, Family and Psychosis
PLOS ONE | DOI:10.1371/journal.pone.0160949 August 11, 2016 10 / 16
might predate the onset of FEP and could be genetically transmitted in some patients. In fact,
there is evidence of cognitive impairment in relatives of patients with psychosis [49–55]. In a
study performed by Gur et al. [53], unaffected offspring, monozygotic and dizygotic co-twins,
and other relatives, had deficits in episodic memory, working memory, and attention. Cogni-
tive deficits have also been found in siblings when compared to healthy control subjects [56,57]
and in the offspring of patients with schizophrenia [23,53]. Other studies that have compared
IQ in patients with and without FH have also found that both patients and their relatives had
lower global IQ than healthy controls [19,21–23], while patients with no affected relatives had
higher estimated premorbid IQ [58]. A recent study conducted by Derks et al. [59] concluded
that FH+ patients showed more positive symptoms than FH- patients, but no differences were
found as regards IQ, cannabis abuse, or age at onset. In our sample of FEP patients, patients
with and without FH also had a poorer estimated premorbid IQ than healthy controls; there
were no differences between patient groups.
This study has several strengths. First, it is a multi-centre study that includes a large sample
of patients and controls recruited in multiple Spanish psychiatric admission centres for acute
psychosis, meaning that generalizability of the results is ensured. Second, the study comprised
child and adolescent patients, in addition to adults. This wide age window allows the collection
of a more representative sample, with an average age (23.63±5.9) lower than that for other
studies with large FEP cohorts (OPUS trial: 26.6±6.4; EUFEST trial: 26±5.6), which did not
include child and adolescent patients [60,61]. Third, unlike other FEP studies, such as EUFEST
[62,63], the neuropsychological battery used was extensive and covered the areas proposed by
the NIMH-MATRICS consensus (except visual memory) [64,65].
Nevertheless, this study has some limitations that must be taken into account when inter-
preting the findings. These limitations include the naturalistic setting of the study, from which
causal inferences cannot be drawn. A further limitation is that it would be necessary to assess
patients during follow-up to ensure longitudinal stability. Although one of the inclusion crite-
ria was that the control group did not have FH, it would be interesting to consider an FH+ con-
trol group. It has also been assumed that various combinations of FH carry equivalent genetic
loadings. However, patients could have different genetic loadings (one vs. multiple family
members affected). Another limitation is that type of cannabis use was not measured. Finally,
future studies should analyse cognition in relatives of patients, in addition to the relationship
between cognition, FH of psychosis, and extent of cannabis use.
Although further studies are required to improve the understanding of the influence of FH
on the association between cannabis use and cognition in FEP patients, our findings show that
cannabis use is associated with better performance in patients with an FH of psychosis and a
worse performance in those with no FH of psychosis in the verbal-memory, executive-function
and global-cognition domains.
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